Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type.

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an exceedingly rare extra-nodal variant of diffuse large B-cell lymphoma (DLBCL) with an aggressive natural history that often manifests as red cutaneous tumour lesions on the lower extremities. Additionally, with the chemoresistant nature of PCDLBCL-LT and the relatively poor prognosis, many patients experience disease relapse and thus, novel treatment paradigms are needed for salvage therapy. PET/CT 13 months after starting therapy shows continued CR, and the patient remains in remission clinically at 20 months. After four cycles of therapy, an interim PET/CT scan demonstrated a CR with no hypermetabolic uptake to indicate active, recurrent, or metastatic disease. [Extracted from the article]